Monograph Details
|
|
Respiratory Tract
> Rhinitis/rhinorrhea (intranasal products)
|
|
NASACORT AQ |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Triamcinolone acetonide 55micrograms/spray; aqueous nasal spray. |
| Indications |
|
Seasonal and perennial allergic rhinitis. |
| Children |
|
<2yrs: not recommended. 2–5yrs: 1 spray in each nostril once daily. 6–12yrs: 1 spray in each nostril once daily; max 2 sprays in each nostril once daily. Reduce dose as condition improves. |
| Adults |
|
2 sprays in each nostril once daily. Reduce dose as condition improves. |
| Precautions |
|
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. Avoid use in patients with recent nasal ulcers, surgery, or trauma. Reevaluate if no improvement in 3 weeks. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), changes in vision or increased intraocular pressure, and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Pharyngitis, epistaxis, flu syndrome, cough increased, bronchitis, headache, pharyngolaryngeal pain, nasopharyngitis, abdominal upper pain, GI upset; glaucoma/cataracts, impaired wound healing, reduced growth velocity in children. |
| How Supplied |
|
Nasacort AQ—16.5g (120 sprays) |
|
|
|
|
